Blog
RSS FeedPosted by Michael Wonder on 20 Sep 2021
Alvotech provides update on FDA action regarding AVT02, proposed high concentration biosimilar to Humira (adalimumab)
20 September 2021 - Alvotech today announced that the FDA is deferring action on the application for AVT02, the company’s proposed ...
Posted by Michael Wonder on 20 Sep 2021
FDA approves first biosimilar to treat macular degeneration disease and other eye conditions
17 September 2021 - The U.S. FDA today approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the ...
Posted by Michael Wonder on 18 Sep 2021
Alvotech welcomes positive CHMP opinion for AVT02, a proposed biosimilar to Humira
17 September 2021 - Alvotech today welcomed the positive opinion of the EMA's CHMP recommending the approval of Alvotech‘s high-concentration AVT02 ...
Posted by Michael Wonder on 26 Aug 2021
CVS juggles biosimilar options on its formulary
27 August 2021 - Whether payers put biosimilars on formulary, versus originator products, depends in large part on the respective ...
Posted by Michael Wonder on 26 Aug 2021
PHARMAC seeks feedback on a biosimilar brand of adalimumab being considered for funding
26 August 2021 - PHARMAC is considering awarding Principal Supply to a biosimilar brand of adalimumab (Amgevita) from 1 February ...
Posted by Michael Wonder on 25 Aug 2021
Avastin biosimilar may bring insurance benefits for Tecentriq
25 August 2021 - The government has been delaying discussing whether to allow reimbursement for Tecentriq (atezolizumab) due to concerns ...
Posted by Michael Wonder on 23 Aug 2021
Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz
23 August 2021 - Novartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the ...
Posted by Michael Wonder on 09 Aug 2021
Ophthalmologist group wants U.S. Government to push back against Avastin biosimilars
10 August 2021 - The American Academy of Ophthalmology says biosimilar alternatives to Avastin have never been tested in the ...
Posted by Michael Wonder on 09 Aug 2021
Barriers to US biosimilar market growth: lessons from biosimilar patent litigation
6 August 2021 - High biologic drug prices have placed substantial strain on the US health care system. ...
Posted by Michael Wonder on 09 Aug 2021
Competition from biosimilars drives price reductions for biologics in the French single payer health system
6 August 2021 - France has a single payer health insurance system that has the authority to impose pharmaceutical price reductions ...
Posted by Michael Wonder on 06 Aug 2021
Formycon and Bioeq announce submission of the biologics license application for FYB201, a biosimilar candidate to Lucentis (ranibizumab) to the U.S. FDA
5 August 2021 - Formycon and its license partner Bioeq announce that the biologics license application for FYB201, Formycon’s biosimilar ...
Posted by Michael Wonder on 28 Jul 2021
FDA approves first interchangeable biosimilar insulin product for treatment of diabetes
28 July 2021 - Availability of insulin products will help increase access and potentially lower the cost of insulin for people ...
Posted by Michael Wonder on 27 Jul 2021
J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
27 July 2021 - In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a ...
Posted by Michael Wonder on 21 Jul 2021
Sorrento announces its partner Mabpharm has received marketing approval in China for infliximab biobetter
20 July 2021 - Sorrento to exclusively market the product outside of China including US, Japan and Europe. ...
Posted by Michael Wonder on 02 Jul 2021
Formycon and Bioeq announce submission of the marketing authorisation application for FYB201, a biosimilar candidate to Lucentis (ranibizumab) to the EMA
29 June 2021 - Formycon and its license partner Bioeq AG announce that the marketing authorisation application for FYB201, Formycon’s ...